View Older Stories View More Recent Stories

Jun 4, 2016 02:27PM Opdivo® (nivolumab) and Yervoy® (ipilimumab) Combination Regimen Shows Clinically Meaningful Responses in First-Line Advanced Non-Small Cell Lung Cancer, In Updated Phase 1b Study CheckMate -012
May 31, 2016 10:30AM Bristol-Myers Squibb to Take Part in Goldman Sachs 37th Annual Global Health Care Conference
May 24, 2016 09:26AM ARIAD Pharma (ARIA) Taps Bristol-Myers Squibb's Herron as Chief Commercial Officer
May 23, 2016 11:15AM Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 19, 2016 07:55AM Inovalon Announces Agreement with Bristol-Myers Squibb to Focus on Real World Outcomes & Value-Based Contracting Initiatives
May 18, 2016 05:40PM Two-Year Overall Survival Data from Two Pivotal Opdivo® (nivolumab) Trials Demonstrate Sustained Benefit In Patients with Advanced Non-Small Cell Lung Cancer
May 18, 2016 06:59AM Breadth and Depth of Bristol-Myers Squibb’s Immuno-Oncology Clinical Development Program to be Showcased at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
May 18, 2016 06:24AM Bristol-Myers Squibb (BMY) Affirms FDA Expanded Approval of Opdivo as Treatment of Certain cHL
May 17, 2016 07:04PM Opdivo® (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transpla
May 17, 2016 01:00PM Bristol-Myers Squibb Opens Expanded Biologics Facility
May 11, 2016 02:26PM Bristol-Myers Squibb (BMY), AbbVie (ABBV) Announce EC Approval of Empliciti Combo as Multiple Myeloma Treatment
May 11, 2016 02:25PM Bristol-Myers Squibb and AbbVie Announce European Commission Approval of Empliciti™ (elotuzumab) for the Treatment of Multiple Myeloma in Adult Patients Who Have Received at Least One Prior Therapy
May 11, 2016 11:32AM Bristol-Myers Squibb (BMY) Receives EC Approval for Opdivo + Yervoy Combo for Treatment of Advanced Melanoma
May 11, 2016 11:31AM European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo® (nivolumab) + Yervoy® (ipilimumab) Regimen, for Treatment of Advanced Melanoma
May 5, 2016 07:30AM Modern Family Star Eric Stonestreet and His Mom, a Two Time Cancer Survivor, Join Forces to Raise Awareness of Immuno-Oncology Research through Ready. Raise. Rise. Campaign
Apr 28, 2016 06:59AM Bristol-Myers Squibb Reports First Quarter Financial Results
Apr 27, 2016 10:00AM Bristol-Myers Squibb to Take Part in Deutsche Bank Annual Health Care Conference
Apr 25, 2016 07:06AM Bristol-Myers Squibb's (BMY) Opdivo Granted FDA Breakthrough Therapy Designation in Metastatic SCCHN
Apr 25, 2016 06:59AM Bristol-Myers Squibb’s Opdivo® (nivolumab) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Previously Treated Recurrent or Metastatic Squamous Cell Carcinoma of
Apr 20, 2016 05:32PM Medidata Solutions (MDSO) Announces Bristol-Myers Squibb (BMY) Selected Medidata Clinical Cloud
Apr 20, 2016 05:30PM Bristol-Myers Squibb Selects Medidata Clinical Cloud® to Drive Drug Development and Business Transformation
Apr 19, 2016 09:31AM Bristol-Myers Squibb (BMY) Announces Presentation of Significant Opdivo Phase 3 Data in SCCHN
Apr 19, 2016 09:30AM First Presentation of Overall Survival Data for Opdivo® (nivolumab) Shows Significant Survival Benefit at One-Year Versus Investigator’s Choice in Recurrent or Metastatic Squamous Cell Carcinoma of
Apr 17, 2016 03:15PM First Presentation of Two-Year Overall Survival Data for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) Showed Superior Efficacy Versus Yervoy Alone in Advanced Melanoma
Apr 14, 2016 07:00AM Bristol-Myers Squibb (BMY) Announces U.S. FDA Acceptance of Opdivo sBLA fro cHL Following Therapies
Apr 14, 2016 06:59AM U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Supplemental Biologics License Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lympho
Apr 6, 2016 11:46AM Bristol-Myers Squibb (BMY) Opdivo Approved in Europe for Advanced RCC
Apr 6, 2016 11:45AM European Commission Approves Bristol-Myers Squibb’s Opdivo® (nivolumab) for Previously Treated Advanced Renal Cell Carcinoma
Apr 6, 2016 11:13AM Bristol-Myers Squibb (BMY) Announces EC Approval of Expanded Opdivo Indication
Apr 6, 2016 11:12AM European Commission Approves Expanded Use of Opdivo® (nivolumab) to Include Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Apr 4, 2016 09:27AM Bristol-Myers Squibb (BMY) Announces Completion of Padlock Therapeutics Acquisition
Apr 1, 2016 04:15PM Bristol-Myers Squibb Completes Previously Announced Acquisition of Padlock Therapeutics, Inc.
Apr 1, 2016 11:52AM Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) in Combination with Yervoy® (ipilimumab) for Treatment of Advanced Melanoma
Mar 30, 2016 04:17PM Bristol-Myers Squibb (BMY) Announces EMA Validation of Opdivo-Related Type 2 Variation Application
Mar 30, 2016 04:15PM European Medicines Agency Validates Bristol-Myers Squibb’s Application for Opdivo® (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients
Mar 30, 2016 07:46AM Pfizer (PFE), Bristol-Myers Squibb (BMY) Will Present 16 Abstracts at ACC.16
Mar 30, 2016 07:45AM Bristol-Myers Squibb and Pfizer Announce Global Real-World Data Program and Present New Analyses of Eliquis (apixaban) at the American College of Cardiology’s 65th Annual Scientific Session
Mar 24, 2016 02:00PM Bristol-Myers Squibb to Present at William Blair Conference, Cancer Immunotherapy: A Long-Awaited Reality
Mar 23, 2016 07:00AM Bristol-Myers Squibb (BMY) Enters Agreement to Acquire Padlock Therapeutics in ~$600M Deal
Mar 23, 2016 06:59AM Bristol-Myers Squibb to Acquire Padlock Therapeutics, Inc.
Mar 16, 2016 04:32PM Bristol-Myers Squibb (BMY) Will Present New Opdivo, Yervoy Data Overall Survival Data at AACR 2016
Mar 16, 2016 04:30PM Bristol-Myers Squibb to Present New Overall Survival Data for Opdivo® (nivolumab) as Monotherapy and in Combination with Yervoy® (ipilimumab) at the AACR 2016 Annual Meeting
Mar 16, 2016 03:00AM Allied-Bristol Life Sciences Launches iβeCa Therapeutics from NYU School of Medicine to Develop Novel Cancer Therapeutics Targeting the Wnt Pathway
Mar 15, 2016 11:00AM Bristol-Myers Squibb to Announce Results for First Quarter 2016 on April 28
Mar 9, 2016 10:30AM Bristol-Myers Squibb to Present at Barclays Global Health Care Conference
Mar 7, 2016 06:59AM Bristol-Myers Squibb and LabCentral Team Up in Cambridge, Massachusetts to Support Promising Biotech Startup Companies
Mar 3, 2016 04:15PM Bristol-Myers Squibb Announces Dividend
Mar 3, 2016 02:27PM Bristol-Myers Squibb (BMY) Adds Integra LifeSciences CEO Arduini as Director
Mar 3, 2016 01:15PM Bristol-Myers Squibb Names Peter J. Arduini to Board of Directors
Feb 29, 2016 10:00AM Bristol-Myers Squibb to Present at Cowen and Company Annual Global Health Care Conference
View More Recent Stories View Older Stories